In July 2025, AI-driven drug discovery company CALICI and a joint research team from Yeungnam University(YU) announced groundbreaking results that could shift the paradigm in drug toxicity prediction. Their…

*(MAE : Mean absolute error) [Ranked No.1 with AI Technology] Calici’s proprietary model ‘CaliciBoost’ achieved the best performance (MAE 0.256)! Calici, a bio-AI startup, announced that it has secured…

Calici’s research team is proud to announce the publication of our second co-authored paper.This study centers on blood glucose regulation through activation of the insulin signaling pathway, presenting significant…

At BIO KOREA 2025 held at COEX, Seoul, CALICI participated as both a booth exhibitor and panelist, highlighting innovations in AI-based toxicity prediction and alternative testing methods that reduce…

Calici’s AI-based drug discovery platform, Pharmaco‑Net®, has contributed to its first customer joint research paper, now published in PNAS. The study demonstrates Calici’s approach of “result-driven AI drug discovery”…

CALICI and CellFree Sciences Sign Strategic Partnership to Accelerate Drug Discovery between Korea and Japan CALICI, a protein structure-based AI drug discovery (SBDD) company headquartered in the U.S. and…

CALICI (CEO Jaemoon Choi), a leader in AI-driven drug discovery and the biotech industry, has signed a strategic industry-academia cooperation MOU with Kyungbok University (President Jiyong Jeon). The partnership…

On January 12, CALICI participated in the 82 Startup Summit, the largest Korean startup event in Silicon Valley, held at the Plug and Play headquarters in Santa Clara. The…

Founded in October 2020 by protein structure specialist Jaemoon Choi, CALICI has developed Pharmaco-Net®, an AI-powered SaaS platform for drug candidate discovery. The platform integrates multiple AI models to…

CALICI (CEO Jaemoon Choi), an AI-based drug discovery platform company, has signed an MOU with global compound supplier Enamine to collaborate on compound supply and the development of new…

On August 20, Seo-gu District in Daejeon announced its plan to cooperate with the Japan External Trade Organization (JETRO) to help Korean and Japanese companies expand into each other’s…

CALICI has officially relocated and expanded its headquarters to Daejeon Startup Park in Gung-dong, Yuseong-gu, Daejeon. The move provides the company with a larger 14-person office, offering a more…

Uiseong County(Daegu Region) and CALICI Sign MOU to Foster Cell Culture Industry and Develop New Natural-Product Materials Uiseong County and CALICI have signed a memorandum of understanding (MOU) to…

On August 5, MarkHelts (CEO Seungmin Lee) and CALICI (CEO Jaemoon Choi) signed a memorandum of understanding (MOU) to collaborate on AI-driven CAR-T therapies targeting solid tumors, as well…

AIMS Bioscience, a drug development consulting company led by CEO Dongseok Lim, announced on the 28th that it has signed a strategic agreement with Calici, an AI-driven drug discovery…

At this June’s Demo Day, Korea Technology Finance Corporation (KIBO) showcased 16 outstanding startups selected from 60 innovative companies it has discovered. The event was attended by accelerators, venture…

Calici has been selected as one of the innovative startups to join the 12th KIBO Venture Camp, an accelerating program organized by the Korea Technology Finance Corporation (KIBO) in…

K-Medi Hub (Daegu-Gyeongbuk Medical Innovation Foundation) announced a joint research collaboration with Calici, led by CEO Jae-Mun Choi, to develop next-generation therapeutics targeting infectious diseases. While current COVID-19 treatments…

Calici, an AI-driven drug discovery platform company led by CEO Jae-Mun Choi, announced on the 16th that it has signed a Memorandum of Understanding (MOU) with Cureverse, a small-molecule…